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It is known that interferon-g (IFN-g) is produced by activated T and NK lymphoid cells, mononuclear cells, and macrophage and
dendritic cells. Our previous studies have shown that IFN-g-like immunoreactivity also appears in human adrenal cortical tumour and
phaeochromocytoma. To investigate whether human tumour cells can produce IFN-g, we examined 429 biopsy specimens of 30
kinds of tumour and tumour-surrounding tissues in adrenal glands and in kidneys by using immunohistochemistry and in situ
hybridisation. IFN-g immunoactivity was shown in 34.3% of the adrenal cortical adenomas, 50% of the adrenal cortical carcinomas,
26.7% of the phaeochromocytomas, 26.7% of the clear cell renal cell carcinomas (RCCs), 22% of the adrenal cortexes and 40% of
medullas adjacent to tumours. The positive samples and expression areas were well overlapped between the IFN-g mRNA and the
immunohistochemistry staining. Western blot analysis has further confirmed the immunohistochemistry results by showing a distinct
IFN-g band corresponding to 17.4kDa in tissue extracts from adrenal cortical adenoma, phaeochromocytoma and clear cell RCCs.
These results indicate that IFN-g is produced by some types of tumour cells, suggesting it may play a dual role in the development of
these tumours.
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Interferon-g (IFN-g) is a multi-functional cytokine produced
mainly by macrophages, dendritic cells, activated T lymphocytes
and NK cells (Tripp et al, 1993; Gessani and Belardelli, 1998; Fukao
et al, 2000; Murphy et al, 2000). In addition to its well-known
antiviral activities, IFN-g also plays a role in host antitumor
responses. Endogenously produced IFN-g is reported to function
in cancer immunosurveillance, protecting the host against the
growth of transplanted tumours and the formation of primary,
chemically induced spontaneous tumours (Shankaran et al, 2001;
Street et al, 2001). Mice deficiency of IFN-g signalling developing
spontaneous tumours at a higher frequency than normal mice
further indicates that IFN-g is involved in immune response to
tumours (Kaplan et al, 1998). IFN-g also regulates cell proliferation
and apoptosis via activating the downstream JAK–STAT signalling
pathway (Buard et al, 1998; Haque and Williams, 1998; Weber-
Nordt et al, 1998; Lee et al, 2000). IFN-g-like immunoreactivity has
been proved to appear in human adrenal cortical tumours,
phaeochromocytomas and hepatocellular carcinomas (HCCs) by
immunohistochemical method (Li and Song, 1995, 1996; Chia et al,
2002). However, immunohistochemistry analysis alone cannot
confirm whether tumour cells produce IFN-g. To answer this
question, we used immunohistochemistry combined with in situ
hybridisation and Western blot method to screen a cluster of
different types of tumours.
MATERIALS AND METHODS
Biopsy material
A total of 429 biopsy specimens of 30 kinds of tumour and three
types of tumour-surrounding tissues were collected from patients
who had not received any chemotherapeutic or immunomodula-
tory treatment before operations. Tumour tissues were classified
according to the classification system of the World Health
Organization (Table 1). Tissue specimens were fixed for 18–24h
in 10% buffered formalin and routinely processed to paraffin
embedding.
Immunohistochemistry
Serial sections from each case were stained with a mouse
monoclonal antibody specific to human IFN-g (United States
Patent 4599306, Department of Immunology, Fourth Military
Medical University, Xi’an, China). This antibody has optimised
specificity by using the method of microwave antigen retrieval on
formalin-fixed, paraffin-embedded tissue. Immunohistochemical
staining was performed using a standard streptavidin–biotin–
peroxidase complex (SABC) (BOSTER Incorporation, Wuhan,
China). Visualisation was performed using diaminobenzidine
(DAB) for the horseradish peroxidase. The sections were counter-
stained with haematoxylin, dehydrated and mounted. A positive
control was performed using the L26 (anti-CD20) monoclonal
antibody (Dako, Glostrup, Denmark) a marker of B lymphocytes.
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with non-immune mouse serum.
Immunoblotting
Fresh tissue samples from six cases of adrenal cortical adenomas,
five cases of phaeochromocytomas, five cases of clear cell renal cell
carcinomas (RCCs) and one case of colonic adenocarcinoma were
cut into small pieces and homogenised using a Polytrope high-
speed metal homogeniser (Brinkmann Instruments, Westbury, NY,
USA) in five volumes of 50mmoll
 1 Tris buffer (pH 7.7)
containing 0.5mmoll
 1 phenylmethylsulphonylfluoride to inhibit
proteolysis. The supernatant was obtained after centrifugation at
12000r.p.m.min
 1 for 15min at 41C. A volume of 1ml supernatant
from each sample was dot blotted on a polyvinylidene fluoride
(PVDF) paper. Immunostaining was performed using a standard
SABC (BOSTER Incorporation). Negative control was obtained
by replacing the primary antibody with non-immune mouse
serum.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and Western blot analysis
The dot blotting positive samples (two from adenomas, one from
phaeochromocytoma and one from clear cell RCCs) and one
negative colonic carcinoma were separated by 15% SDS–
polyacrylamide gels (PAGE). Molecular weight markers (C-6210;
Sigma Chemical Co, St Louis, MO, USA) were run together with the
samples. After the separation, the proteins were electroblotted onto
PVDF paper utilising the Phast system. The PVDF membranes
were blocked by incubation in 0.02moll
 1 Na2HPO4, 0.15moll
 1
NaCl, pH 7.2 containing 0.05% Tween 20 and 3% bovine serum
albumin for 1h at room temperature and then followed by
immunoblotting. Negative control was obtained by replacing the
primary antibody with non-immune mouse serum.
In situ hybridisation analysis
In situ hybridisation for IFN-g mRNA was performed on further
serial sections from 35 cases of adrenal cortical adenomas, four
cases of adrenal cortical carcinomas, 30 cases of phaeochromo-
cytomas, 60 cases of clear cell RCCs, 10 cases of HCCs, nine cases of
tumour surrounding adrenal cortexes, five cases of medullas and
23 cases of tumour around renal tissues by using an oligonuclear-
tide IFN-g kit (BOSTER Incorporation). The experiment was
performed according to the instruction. Briefly, after de-waxing
and re-hydration, sections were pretreated with 0.3% hydrogen
peroxide to suppress the endogenous peroxide. Tissues were
postfixed with 1% paraformaldehyde and were further reacted with
prehybridisation solution. A volume of 30ml hybridisation solution
was supplied on each tissue section with glass coverslips and
incubated overnight at 38–421C. Coverslips were removed and the
sections were washed. After blocking solutions, the sections were
incubated with biotinilated mouse-anti-digoxingin for 1h at 371C.
The sections were then washed thoroughly and incubated with
SABC at room temperature. Visualisation was performed by using
DAB. The sections were counterstained with haematoxylin, then
dehydrated and mounted.
Table 1 Biopsy specimens
Age
Histopathological diagnosis Total case number Male Female Median Range
Tumour around adrenal cortex 9 6 3 43 28–56
Tumour around adrenal medulla 5 4 1 41 26–48
Adrenal cortical adenoma 35 21 14 45 28–64
Adrenal cortical carcinoma 4 4 0 49 35–57
Phaeochromocytoma 30 17 13 41 12–48
Tumour around kidney 23 19 4 54 51–68
Clear cell RCC 60 47 13 56 42–73
Hemangioma 10 4 6 21 12–36
Fibroadenoma of breast 10 0 10 49 35–59
Ovarian teratoma 10 0 10 29 19–36
Leiomyoma 10 0 10 43 26–56
Pituitary adenoma 10 0 10 38 32–47
Thyroid adenoma 10 2 8 36 21–43
Intestinal adenoma 10 7 3 29 16–49
Ovarian adenoma 10 0 10 23 18–31
Cutaneous papilloma 10 6 4 32 16–46
Gastric carcinoma 10 6 4 52 38–73
Intestinal carcinoma 10 7 3 47 29–69
Breast carcinoma 10 8 2 56 39–76
Thyroid carcinoma 10 3 7 43 34–58
Pancreatic carcinoma 10 7 3 56 43–74
Bladder carcinoma 10 10 0 63 41–78
Larynx squamous carcinoma 10 10 0 51 35–67
Squamous carcinoma of skin 10 4 6 47 44–63
Cervical squamous carcinoma 10 0 10 54 41–69
Nasopharyngeal carcinoma 10 9 1 46 32–58
Lung cancer 10 6 4 62 24–84
Meningeoma 10 6 4 32 14–37
Astrocytoma 10 7 3 48 16–70
Rhabdomyosarcoma 10 7 3 12 6–48
Osteosarcoma 10 10 0 19 14–33
Fibrosarcoma 10 5 5 16 17–42
Hepatocellular carcinoma 10 4 6 43 34–51
RCC, renal cell carcinomas.
Expression of IFN-c in human adrenal gland and kidney tumours
QL iet al
421
British Journal of Cancer (2007) 97(3), 420–425 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sControls were processed with the omission of the probe and
with mRNase before hybridisation.
Scoring of immunohistochemistry and in situ
hybridisation
The immunoreactivity and in situ hybridisation were scored
according to the staining extension and intensity. The intensity
of staining was scored from 0 to 3: 0 for negative; 1 for weak; 2
for moderate; 3 for strong staining. The extension of immuno-
reactivity was estimated from 0 to 4: 0 for negative; 1 for 1–25%;
2 for 26–50%; 3 for 51–75%; 4 for 76–100% of positive immuno-
reactivity cells. The positive immunoreactivity or in situ hybridisa-
tion staining was determined by the combined staining score
(intensity score plus extent score): 0 for p2; 1 for 3; 2 for 4–5; 3
for 6–7.
RESULTS
Immunohistochemistry
The immunoreactive IFN-g-positive cells displayed distinct brown
staining; immunoreactive materials appearing as densely packed
granules in the entire or focal of cytoplasm, whereas immuno-
staining was undetectable in negative control sections, indicating
that IFN-g immunoreactive staining was specific.
Prominent staining cells for immunoreactive IFN-g was
observed in 12 out of 35 (34.3%) of the adrenal cortical adenomas,
two of four (50%) of the adrenal cortical carcinomas, eight out of
30 (26.7%) of the phaeochromocytomas and 16 out of 60 (26.7%)
of the clear cell RCC. The IFN-g immunoreactivity was mainly
restricted to tumour cells, and was also in some lymph cells and
macrophages but was usually not in other non-tumour cells. The
IFN-g immunoreactivity was also demonstrated in two out of nine
(22%) of the adrenal cortex and two out of five (40%) of the
medulla tissues adjacent to tumours (Figures 1 and 2 and Table 2).
However, IFN-g immunoreactivity could not be detected in renal
tissues surrounding clear cell RCCs. Surprisingly, the rest 260
tumour biopsies, originating from other organs than adrenal gland
and kidney, did not show IFN-g immunostaining in any single
case.
Western blot analysis
A distinct IFN-g band corresponding to 17.4kDa (Figure 3) was
observed in tissue extracts from two out of six cases of the adrenal
cortical adenomas, one out of five cases of the phaeochromo-
cytomas and one out of five cases of the clear cell RCCs. Colonic
adenocarcinoma and negative control did not show positive
staining.
In situ hybridisation analysis
IFN-g mRNA signals could only be seen in the sections reacted
with antisense probe. It has no staining in control sections, which
either have omitted IFN-g probe or have prior incubated with
mRNase. Prominent cytoplasmic staining for IFN-g mRNA were
detected in 13 out of 35 of the adrenal cortical adenomas, two out
of four of the cortical carcinomas, nine out of 30 of the
phaeochromocytomas, 16 out of 60 of the clear cell RCC, two
out of nine of the tumour adjacent tissues in adrenal cortexes and
two out of five of the medullas. No IFN-g mRNA was detected in
the renal tissues surrounding clear cell RCC. The IFN-g expressing
samples and areas were well overlapped in between of mRNA
signal and immunohistochemistry staining (Figure 2).
DISCUSSION
The adrenal gland consists of two distinct types of primary
tumours: one arising from the adrenal cortex, including
adenomas and carcinomas, and the other from the medulla
representing neural crest-derived chromaffin cell tumours
A B C D
E F G H
Figure 1 IFN-g immunoreactivity in (A) adrenal cortical adenoma, (B) cortical carcinoma, (C) phaeochromocytoma, (D) clear cell RCC, tumour adjacent
tissue in (E) adrenal cortex (F) and medulla. The immunoreactive IFN-g-positive cells show distinct brown staining. The immunoreactive materials often
appear as densely packed granules filling the entire or focal of cytoplasm of tumour cells (arrow) and the interstitial tissue is negative (arrowhead). No IFN-g
immunoreactivity is seen in (G) kidney. Clear cell RCC (same case as in D) matched (H) negative control staining do not show any positive staining.
Bar¼50mm.
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s(pheaochromocytomas). RCC is a group of malignancies arising
from the epithelium of the renal tubules. Clear cell RCC, one type
of RCC, is composed of cells with clear or eosinophilic cytoplasm
within a delicate vascular network.
Our previous study has demonstrated that IFN-g-like immuno-
reactivity appeared in the cytoplasm of tumour cells in adrenal
cortical adenoma, cortical carcinoma and pheochoromocytoma by
using DB1 monoclonal antibody (Li and Song, 1995, 1996). The
IFN-g-like immunoreactivity is not a non-specific binding, since
no staining was detected in the absence of primary antibody. In
addition, DB1 monoclonal antibody is a high-affinity antibody
against rat IFN-g with specific labelling of different molecular
forms of recombinant rat IFN-g, inhibiting biological effects of
IFN-g in vitro and in vivo (Jacob et al, 1987; van der Meide et al,
1986). However, DB1 is a monoclonal antibody against rat IFN-g
but not human IFN-g. In the present study, a monoclonal mouse-
anti-human IFN-g antibody was used to characterise the IFN-g
immunoactivity in 429 human biopsy samples from 30 different
types of tumours and tumour-surrounding tissues in adrenal
glands and in kidneys. The results showed that 34.3% of the
adrenal cortical adenomas, 50% of the adrenal cortical carcinomas,
26.7% of the phaeochromocytomas and 26.7% of the clear cell RCC
expressed IFN-g immunoactivity. IFN-g was not detectable in other
types of tumour. Western blot analysis revealed IFN-g band
corresponding to 17.4kDa in tissue extracts from two out of six
cases of the adrenal cortical adenomas, one out of five cases of the
phaeochromocytomas and one out of five cases of the clear cell
RCCs, whereas the colonic adenocarcinoma and the negative
control did not show any band. The results suggest that the IFN-g
immunoactivity is specific.
To confirm that the IFN-g is indeed produced in tumour cells,
IFN-g mRNA in situ hybridisation was performed on the same
biopsy samples. The in situ hybridisation results confirmed our
hypothesis that the transcripts of IFN-g genes were inside the
adrenal and RCC tumour cells. The mRNA expressing tissues were
overlapped with the immunohistochemistry staining, indicating
that the IFN-g protein was generated by tumour cells. IFN-g
protein and mRNA levels were generally higher in adrenal cortical
adenomas than in cortical carcinomas. Clear cell RCCs expressed
both mRNA and IFN-g protein, but not in the tumour-surrounding
renal tissue. Therefore, IFN-g expression may in some way
correlated to the tumour malignancy level or cell differentiation.
It remains unclear why IFN-g was expressed in 22% of tumour
surrounding tissue in adrenal cortexes and 40% of in medullas.
Cells with IFN-g-like immunoreactivity have also been reported in
type II alveolar epithelial cells in interstitial lung disease (Wallace
and Howie, 1999), rat neurons (Kiefer et al, 1991), rat skeletal
A B C D
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Figure 2 In situ hybridisation for IFN-g mRNA. The IFN-g mRNA signals are seen in adrenal (A) cortical adenoma, (B) cortical carcinoma, (C)
phaeochromocytoma, (D) clear cell RCC, tumour adjacent tissue (E) in adrenal cortex (F) and medulla. IFN-g mRNA is apparent in the cytoplasm of
parenchyma cells (arrow), not in interstitial tissue (arrowhead). IFN-g mRNA signals are not seen in HCC (G). Adrenal cortical carcinoma (same case as in
B) matched negative control with (H) mRNase do not show any positive staining. Bar¼50mm.
Table 2 IFN-g immunoreactivity in tumours and tumours adjacent
tissues
Score
Type Case no. 0 1 2 3 Positive no. %
ACA 35 23 2 7 3 12 34.3
ACC 4 2 0 0 2 2 50.0
Phaeo 30 22 0 4 4 8 26.7
CRCC 60 44 5 8 3 16 26.7
TAC 9 7 0 0 2 2 22.2
TAM 5 3 0 1 1 2 40.0
AC, tumour around adrenal cortex; ACA, adrenal cortical adenoma; ACC, adrenal
cortical carcinoma; Phaeo, phaeochromocytoma; CRCC, clear cell renal cell
carcinoma; IFN-g, interferon-g; TAM, tumour around adrenal medulla.
20 kDa
14 kDa
12345 6
Figure 3 Western blot analysis for IFN-g. A 17.4kDa IFN-g protein band
appears in the extracts from adrenal cortical adenomas (lanes 1 and 2),
clear cell RCC (lane 3) and pheochromocytoma (lane 4). Negative control
(lane 5, same case as in lane 1) and colonic adenocarcinoma (lane 6) do not
show any band.
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smuscle (Nennesmo et al, 1989), transplanted rat heart tissue
(Wanders et al, 1992), astrocytes in active chronic multiple
sclerosis lesion (Traugott and Lebon, 1988) and cerebrovascular
endothelial cells from aged mice (Wei et al, 2000). However, there
was no further report about the significance of the IFN-g
expression in those tissues or cells. IFN-g has also been reported
weakly expressed in HCCs (Chia et al, 2002). But in the present
study, neither protein nor mRNA of IFN-g was expressed in the 10
cases of HCCs, probably because that the methods we used are not
sensitive enough.
It is well known that IFN-g contributes to the increased
antitumour activity of immune cells, though the reason why some
tumour cells produce IFN-g is not clear. Previous studies have
established that testicular germ cell tumour cells can express both
mRNA and protein of IFN-g and the expressed IFN-g is able to
induce the chemokine IP-10, indicating its biological activity,
whereas it is not able to phosphorylate the downstream STAT1
(Schweyer et al, 2002, 2003). A number of tumours and tumour cell
lines have also been reported to develop a permanent and selective
IFN-g insensitivity, such as testicular germ cell tumours, RCC
cell line, basal cell carcinoma of the skin and human lung adeno-
carcinoma cell lines (Kooy et al, 1998; Dovhey et al, 2000; Nagao
et al, 2000; Schweyer et al, 2002, 2003; Dunn et al, 2005b). Such
insensitivity to IFN-g is due to lack of expression of IFN-g
receptors or the receptor downstream genes. Tumour cells can
naturally develop mutations on IFN-g downstream target genes,
such as JAK and Stat1, to render them insensitive to IFN-g.
Recently, a concept of cancer immunoediting has been put
forward (Ikeda et al, 2002; Dunn et al, 2004a,b, 2005a,b, 2006). It
is a process consisting of three phases: elimination (i.e., cancer
immunosurveillance), equilibrium and escape. The immune
system not only protects the host against development of primary
nonviral cancers but also sculpts tumour immunogenicity. Thus,
IFN-g may play a dual role in preventing development of primary
and transplanted tumours on one hand, and sculpting the
immunogenic phenotype of tumours on the other. Tumour escape
may be attributable to tumour genetic changes that affect tumour
recognition by immune effective cells (such as, loss of antigen
expression, loss of MHC components, shedding of NKG2D ligands
and development of IFN-g insensitivity) or provide tumours with
mechanisms to escape immune destruction (such as, defects in
death-receptor signalling pathways or expression of antiapoptotic
signals including constitutively active STAT3). The dysregulation
of MHC class I processing and presentation, or/and development
of IFN-g insensitivity in tumour cells, would allow tumours to
escape from the elimination phase of the cancer immunoediting
process (Dunn et al, 2004b). However, whether the specific
expression of IFN-g in tumours from adrenal gland and kidney
is correlated with tumour escape is not clear and needs to be
further elucidated.
In conclusion, we provide solid evidence that tumour cells express
IFN-g protein and mRNA especially in adrenal gland and kidney
tumours. Our findings give a further insight into the role of IFN-g in
the pathogenesis of tumour, which will be critical for effective
immunotherapeutic approaches for cancer therapy in the future.
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